Treatment Of Type 2 Diabetes With Hepatocyte Nuclear Factor 4 Alpha (HNF4A) Agonists

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20240207204A1
SERIAL NO

18535052

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure generally relates to the treatment of subjects having Type 2 diabetes and/or chronic kidney disease or at risk of developing Type 2 diabetes and/or chronic kidney disease by administering a Hepatocyte Nuclear Factor 4 Alpha (HNF4A) agonist to the subject.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
REGENERON PHARMA777 OLD SAW MILL RIVER ROAD TARRYTOWN NEW YORK 10591 10591

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Backman, Joshua Tarrytown, US 11 1
Bovijn, Jonas Tarrytown, US 5 0
Gusarova, Viktoria Tarrytown, US 31 142
Pearson, Gemma Tarrytown, US 1 0
Riaz, Moeen Tarrytown, US 1 0
Shuldiner, Alan Tarrytown, US 26 46

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation